The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients
Identifieur interne : 00B520 ( Main/Exploration ); précédent : 00B519; suivant : 00B521The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients
Auteurs : Laurent Meyer [France] ; Philip Bohme [France] ; Irene Delbachian [France] ; Philippe Lehert [Australie, Belgique] ; Nathalie Cugnardey [France] ; Pierre Drouin [France] ; Bruno Guerci [France]Source :
- Diabetes care [ 0149-5992 ] ; 2002.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
OBJECTIVE-This study was designed to assess the insulin-sparing effect of oral administration of metformin along with a continuous subcutaneous insulin infusion (CSII) for the treatment of type 1 diabetic patients. RESEARCH DESIGN AND METHODS-A total of 62 patients (25 women and 37 men) were studied in a monocenter, randomized, double-blind placebo-controlled study, comparing metformin (850 mg b.i.d.) with placebo in association with CSII during a 6-month period RESULTS-Treatment with metformin was associated with a reduction in daily insulin requirements between V0 and V6 of -4.3 ± 9.9 units (-7.8 ± 18%) compared with an increase with placebo treatment of 1.7 ± 8.3 units (2.8 ± 12.7%) (P = 0.0043). A decrease in basal requirement of insulin was also observed in patients treated with metformin of -2.6 ± 3 2 units (-7.9 ± 23.8%) compared with an increase with placebo treatment of 1.9 ± 5.7 units (8.8 ± 27.1%) (P = 0.023). HbA1c remained unchanged in treatment with metformin and placebo between VO and V6. The number of hypoglycemic events (<60 mg/dl) was similar in both groups. Significant reductions of total cholesterol (P = 0.04) and LDL cholesterol (P = 0 05) were observed in patients treated with metformin. Gastrointestinal events, including diarrhea and abdominal pain, were reported in three patients in the metformin group who discontinued the trial. Mild or moderate gastrointestinal side effects were also reported in eight patients treated with metformin and two patients treated with placebo (P = 0.069). CONCLUSIONS-Metformin was found to he a sale insulin-sparing agent, when used in combination with CSII for the treatment of type 1 diabetes.
Affiliations:
- Australie, Belgique, France
- Grand Est, Lorraine (région), Victoria (État), Île-de-France
- Melbourne, Nogent-sur-Marne, Toul
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 005497
- to stream PascalFrancis, to step Curation: 000C29
- to stream PascalFrancis, to step Checkpoint: 005194
- to stream Main, to step Merge: 00C315
- to stream Main, to step Curation: 00B520
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients</title><author><name sortKey="Meyer, Laurent" sort="Meyer, Laurent" uniqKey="Meyer L" first="Laurent" last="Meyer">Laurent Meyer</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author><author><name sortKey="Bohme, Philip" sort="Bohme, Philip" uniqKey="Bohme P" first="Philip" last="Bohme">Philip Bohme</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author><author><name sortKey="Delbachian, Irene" sort="Delbachian, Irene" uniqKey="Delbachian I" first="Irene" last="Delbachian">Irene Delbachian</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Faculty of Medicine, University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Faculty of Economics, University of Mons</s1><s2>Mons</s2><s3>BEL</s3><sZ>4 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Mons</wicri:noRegion></affiliation></author><author><name sortKey="Cugnardey, Nathalie" sort="Cugnardey, Nathalie" uniqKey="Cugnardey N" first="Nathalie" last="Cugnardey">Nathalie Cugnardey</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>LIPHA Same</s1><s2>Nogent-sur-Marne</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Nogent-sur-Marne</settlement></placeName></affiliation></author><author><name sortKey="Drouin, Pierre" sort="Drouin, Pierre" uniqKey="Drouin P" first="Pierre" last="Drouin">Pierre Drouin</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author><author><name sortKey="Guerci, Bruno" sort="Guerci, Bruno" uniqKey="Guerci B" first="Bruno" last="Guerci">Bruno Guerci</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">03-0048454</idno><date when="2002">2002</date><idno type="stanalyst">PASCAL 03-0048454 INIST</idno><idno type="RBID">Pascal:03-0048454</idno><idno type="wicri:Area/PascalFrancis/Corpus">005497</idno><idno type="wicri:Area/PascalFrancis/Curation">000C29</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">005194</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">005194</idno><idno type="wicri:doubleKey">0149-5992:2002:Meyer L:the:benefits:of</idno><idno type="wicri:Area/Main/Merge">00C315</idno><idno type="wicri:Area/Main/Curation">00B520</idno><idno type="wicri:Area/Main/Exploration">00B520</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients</title><author><name sortKey="Meyer, Laurent" sort="Meyer, Laurent" uniqKey="Meyer L" first="Laurent" last="Meyer">Laurent Meyer</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author><author><name sortKey="Bohme, Philip" sort="Bohme, Philip" uniqKey="Bohme P" first="Philip" last="Bohme">Philip Bohme</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author><author><name sortKey="Delbachian, Irene" sort="Delbachian, Irene" uniqKey="Delbachian I" first="Irene" last="Delbachian">Irene Delbachian</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author><author><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Faculty of Medicine, University of Melbourne</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Faculty of Economics, University of Mons</s1><s2>Mons</s2><s3>BEL</s3><sZ>4 aut.</sZ></inist:fA14><country>Belgique</country><wicri:noRegion>Mons</wicri:noRegion></affiliation></author><author><name sortKey="Cugnardey, Nathalie" sort="Cugnardey, Nathalie" uniqKey="Cugnardey N" first="Nathalie" last="Cugnardey">Nathalie Cugnardey</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>LIPHA Same</s1><s2>Nogent-sur-Marne</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Nogent-sur-Marne</settlement></placeName></affiliation></author><author><name sortKey="Drouin, Pierre" sort="Drouin, Pierre" uniqKey="Drouin P" first="Pierre" last="Drouin">Pierre Drouin</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author><author><name sortKey="Guerci, Bruno" sort="Guerci, Bruno" uniqKey="Guerci B" first="Bruno" last="Guerci">Bruno Guerci</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Service de Diabetologie, Maladies Metaboliques & Maladies de la Nutrition, CIC-INSERM, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy</s1><s2>Toul</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Toul</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Diabetes care</title><title level="j" type="abbreviated">Diabetes care</title><idno type="ISSN">0149-5992</idno><imprint><date when="2002">2002</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Diabetes care</title><title level="j" type="abbreviated">Diabetes care</title><idno type="ISSN">0149-5992</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biguanides</term><term>Chemotherapy</term><term>Cholesterol</term><term>Cholesterol LDL</term><term>Continuous</term><term>Digestive diseases</term><term>Drug combination</term><term>Human</term><term>Insulin</term><term>Insulin dependent diabetes</term><term>Metformin</term><term>Perfusion</term><term>Randomization</term><term>Secondary effect</term><term>Toxicity</term><term>Treatment</term><term>Treatment efficiency</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Diabète insulinodépendant</term><term>Homme</term><term>Traitement</term><term>Metformine</term><term>Chimiothérapie</term><term>Association médicamenteuse</term><term>Insuline</term><term>Randomisation</term><term>Toxicité</term><term>Efficacité traitement</term><term>Perfusion</term><term>Continu</term><term>Cholestérol LDL</term><term>Cholestérol</term><term>Effet secondaire</term><term>Appareil digestif pathologie</term><term>Biguanides</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">OBJECTIVE-This study was designed to assess the insulin-sparing effect of oral administration of metformin along with a continuous subcutaneous insulin infusion (CSII) for the treatment of type 1 diabetic patients. RESEARCH DESIGN AND METHODS-A total of 62 patients (25 women and 37 men) were studied in a monocenter, randomized, double-blind placebo-controlled study, comparing metformin (850 mg b.i.d.) with placebo in association with CSII during a 6-month period RESULTS-Treatment with metformin was associated with a reduction in daily insulin requirements between V0 and V6 of -4.3 ± 9.9 units (-7.8 ± 18%) compared with an increase with placebo treatment of 1.7 ± 8.3 units (2.8 ± 12.7%) (P = 0.0043). A decrease in basal requirement of insulin was also observed in patients treated with metformin of -2.6 ± 3 2 units (-7.9 ± 23.8%) compared with an increase with placebo treatment of 1.9 ± 5.7 units (8.8 ± 27.1%) (P = 0.023). HbA<sub>1c</sub> remained unchanged in treatment with metformin and placebo between VO and V6. The number of hypoglycemic events (<60 mg/dl) was similar in both groups. Significant reductions of total cholesterol (P = 0.04) and LDL cholesterol (P = 0 05) were observed in patients treated with metformin. Gastrointestinal events, including diarrhea and abdominal pain, were reported in three patients in the metformin group who discontinued the trial. Mild or moderate gastrointestinal side effects were also reported in eight patients treated with metformin and two patients treated with placebo (P = 0.069). CONCLUSIONS-Metformin was found to he a sale insulin-sparing agent, when used in combination with CSII for the treatment of type 1 diabetes.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>France</li></country><region><li>Grand Est</li><li>Lorraine (région)</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Melbourne</li><li>Nogent-sur-Marne</li><li>Toul</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="France"><region name="Grand Est"><name sortKey="Meyer, Laurent" sort="Meyer, Laurent" uniqKey="Meyer L" first="Laurent" last="Meyer">Laurent Meyer</name></region><name sortKey="Bohme, Philip" sort="Bohme, Philip" uniqKey="Bohme P" first="Philip" last="Bohme">Philip Bohme</name><name sortKey="Cugnardey, Nathalie" sort="Cugnardey, Nathalie" uniqKey="Cugnardey N" first="Nathalie" last="Cugnardey">Nathalie Cugnardey</name><name sortKey="Delbachian, Irene" sort="Delbachian, Irene" uniqKey="Delbachian I" first="Irene" last="Delbachian">Irene Delbachian</name><name sortKey="Drouin, Pierre" sort="Drouin, Pierre" uniqKey="Drouin P" first="Pierre" last="Drouin">Pierre Drouin</name><name sortKey="Guerci, Bruno" sort="Guerci, Bruno" uniqKey="Guerci B" first="Bruno" last="Guerci">Bruno Guerci</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name></region></country><country name="Belgique"><noRegion><name sortKey="Lehert, Philippe" sort="Lehert, Philippe" uniqKey="Lehert P" first="Philippe" last="Lehert">Philippe Lehert</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00B520 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00B520 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:03-0048454
|texte= The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients
}}
| This area was generated with Dilib version V0.6.33. |  |